A SMART DECISION
For your customers
With a growing product portfolio and dynamic business model, InsulCheck is quickly establishing itself as a leading provider of connected accessories for diabetes management.
We continue to attract longstanding, committed distribution partners with a presence in specific regions or market segments. But our work is not done yet.
We want to expand into key geographic areas and markets through well-established distribution partners and this could be your opportunity to resell desirable, durable medical accessories for one of the largest patient populations in the world.
The World Health Organisation (WHO) estimated that there were 422 million adults with diabetes in 2014.*
Global prevalence is rising at an alarming rate, generating unprecedented financial pressure on health systems and national economies through direct medical costs and loss of wages. In the UK for example, it is currently estimated that about £10 billion is spent by the NHS on diabetes. 10 per cent of the entire NHS budget is spent on diabetes, which works out at roughly £1 Million per hour.^
To help ease the pressure on health systems, patients are encouraged to self-manage highly complex injection routines with self-injection pens.
* Mathers CD, Loncar D (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 3 (11): e442.
^ Hex, N., et al (2012) Estimating the current and future costs of Type 1 and Type 2 diabetes in the United Kingdom, including direct health costs and indirect societal and productivity costs. Diabetic Medicine. 29 (7) 855-862
We understand that distributors work on margins. Our pricing model is designed to provide fair value to all stakeholders - including the customer, distributor and manufacturer.
InsulCheck takes responsibility for driving demand for its products. We are involved in a number of studies that analyse both the health and financial benefits of InsulCheck products.
We can produce custom packaging and labelling in any language. Additional branding opportunities on the device itself are also within scope for certain level of partners.